Valinor Discovery and Renew Biotechnologies are set to collaborate to generate the largest clinical multi-omics dataset to date for neurological disorders.
Designed to improve the prediction of disease onset and therapeutic responses, the initiative will provide Valinor access to multimodal datasets derived from thousands of patients spanning Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders to support large foundation model development.
The collaboration combines Valinor’s work on machine learning with Renew’s quality-controlled, clinical laboratory infrastructure and experience in generating high-resolution multi-omics data from well-characterised patient samples.
Despite advances in technology, neurological drug development remains challenging due to the biological complexity of the central nervous system and the limited availability of clinically relevant human data. By integrating large longitudinal molecular datasets with advanced predictive modelling, the companies aim to address this gap.
Renew will source clinical samples and apply its native-read sequencing workflows within a quality-controlled translational environment to generate genomic and epigenomic data for downstream modelling. Valinor will deploy its proprietary machine learning architectures to identify disease-relevant patterns and predictive signatures of therapeutic response from the longitudinal, multimodal data.
“Predictive models are crucially dependent, not only on the experience of the machine learning team, but also on the quality and relevance of the underlying training data,” said Joshua Pacini, co-founder and CEO of Valinor.
“Renew delivers a rare combination of neurological domain expertise and access to high-quality, longitudinal molecular and clinical data that are relevant to drug development. Paired with our machine learning expertise, this collaboration will offer biopharma teams a stronger foundation to design clinical research programmes with a higher likelihood of success.”
“Neurology programmes often slow or fail when the underlying disease biology is not fully understood,” said Chad Pollard, co-founder and CEO of Renew Biotechnologies.
“Our role is to define and de-risk disease-specific biological signals early, so downstream modelling and development decisions are built on validated biology.”
This partnership aims to increase decision-making confidence, accelerate programmes toward clinical milestones, and reduce R&D costs. Financial terms were not disclosed. The parties will jointly own the resulting datasets, with Valinor serving as the exclusive AI partner authorised to train models from the generated data.